Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyradiotherapyDiseaseEsophageal CancerGastric CancerSubgroupAdenocarcinoma of the esophagogastric junction (AEG)Squamous Cell CarcinomaICD10C15.-C16.-C16.0MeSHEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaStomach NeoplasmsSequenceCAPOX (CAPE1000/OXAL130), AEG/Gastric Ca, adj., A (PID689) -|- B (PID684) -|- C (PID689)DOCE75/CISP75, Esophageal Ca/AEG, neoadj., A (PID1402) -|- DOCE20/CISP25/Radiation, B (PID1403)FU425/CFOL/20/Radiation, AEG/Gastric Ca, adj., A (PID697) -|- B (PID698) -|- C (PID697).ChemotherapyChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidOxaliplatinPaclitaxelVinorelbineChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidOxaliplatinPaclitaxelVinorelbineChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidOxaliplatinPaclitaxelVinorelbineChemo-substanceCapecitabineCarboplatinCisplatinDocetaxelFluorouracilFolinic acidOxaliplatinPaclitaxelVinorelbineNo. Substances23 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideNo. Substances23678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseneoadjuvantseveral possibleTherapy intentioncurativecurative or palliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaAstheniaBleedingCardiotoxicityDiarrheaDysphagiaEmetogenicity (MASCC/ESMO)EsophagitisFebrile NeutropeniaFistulasHyperkalemiaHypocalcemiaHypomagnesemiaHyponatremiaInfectionsLeukopeniaLymphopeniaMucositisNeuropathyNeutropeniaOral MucositisPainPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorConroy THerskovic AHofheinz RDHulshof MCCMLv JMacDonald JSMinashi KRuhstaller TTepper Jvan HagenYang HDiseaseAdenokarzinom des Magens oder gastroösophagealen Übergangs nach R0 Resektion, Stadium Ib-IV, ECOG 0-1Nicht-resektables Adeno- oder Plattenepithelkarzinom des Ösophagus, cT1-4 cN0-3 M0 oder M1 (supraklavikuläre Lymphknoten)nichtresektables Ösophaguskarzinom, Stadium I-IVA, ECOG 0-2Patienten mit operiertem Karzinom des gastroösophagealen Übergangs oder des MagensPotentiell resektables Adeno- oder Plattenepithelkarzinom des Ösophagus.Potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky >90potenziell resezierbares Plattenepithelkarzinom des Ösophagus, Karnofsky > 90resezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1Resezierbares Adenokarzinom des ösophagogastralen Übergangs Typ I und II/Ösophaguskarzinom, Erstlinie, ECOG 0-1Thorakales Plattenepithelkarzinom des Ösophagus, Stadium II-IIIThorakales Ösophagus-Ca, unter 5 cm, T1b N0 M0 mit makroskopisch negativen Resektionsränder oder T1a N0 M0 mit lymphovaskulärer Invasion, nach endoskopischer Resektion, ECOG 0-1Ösophaguskarzinom (Plattenepithel- und Adeno-Ca), Karnofsky Status > 60Ösophaguskarzinom sowie AEG-Tumor Siewert-Typ I/II (Plattenepithel- und Adeno-Ca), cT1-3, cNX, cM0, neu diagnostiziert, Kreatinin-Clearance mind. 50 ml/minOriginausgedehnte MARGIT / AIO StudieClinical Trial Promotion Department, Chiba Cancer Center, Chiba, JapanCROSS-Studiengruppe, Erasmus University Medical Center, Rotterdam, NLDepartment of Radiotherapy, Amsterdam UMC, Amsterdam, the Netherlands, ARTDECO studyDepartment of Thoracic Surgery, Sun Yatsen University Cancer Center, AME Thoracic Surgery Collaborative GroupDépartement d´Oncology Médicale, Vandoeuvre-lés-Nancy, France, PRODIGE5/ACCORD17German Esophageal Cancer Study Group, AGMT, FFCD/FRENCH, SAKK 75/08 trialNanjing Medical University, Nanjing, Jiangsu Province, ChinaNational Institutes of HealthSt. Vincent´s Comprehensive Cancer Center, New YorkUniversity of North Carolina School of Medicine, Chapel Hill, USA, CALGB 9781Protocols in Revision 15 protocols foundCAPOX - Capecitabine 1000 / Oxaliplatin 130, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C (PID689 V1.3)CAPOX / Radiation - Capecitabine 825 / Oxaliplatin 40 / Radiation, adenocarcinoma esophagogastric junction and stomach, adjuvant, Part B (PID684 V1.4)Cisplatin 100 / Fluorouracil 1000 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID1519 V1.2)Cisplatin 70 / Fluorouracil 700 / Radiation, Esophageal Cancer (PID1569 V1.2)Cisplatin 75 / Fluorouracil 1000 / Radiation, Esophageal Cancer (PID281 V1.2)Docetaxel 20 / Cisplatin 25 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part B (PID1403 V1.1)Docetaxel 75 / Cisplatin 75, carcinoma esophagus and gastroesophageal junction, neoadjuvant, part A (PID1402 V1.2)Fluorouracil 400 / Folinic Acid 20 / Radiation, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, Part B (PID698 V1.2)Fluorouracil 425 / Folinic Acid 20, Adenocarcinoma Esophagogastric Junction and Stomach, adjuvant, part A+C. (PID697 V1.2)FOLFOX (Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 1600) / Radiation, Esophageal Cancer (PID694 V1.1)Paclitaxel 135 / Cisplatin 20 / Radiation, Esophageal Cancer, adjuvant (PID2242 V1.0)Paclitaxel 50 / Carboplatin 2 / Radiation, Cancer Esophagus and Gastroesophageal Junction (PID2241 V1.0)Paclitaxel 50 / Carboplatin 2 / Radiation, carcinoma esophagus and gastroesophageal junction, neoadjuvant (PID131 V1.3)Vinorelbine 25 / Cisplatin 25 / Radiation, Esophageal Cancer, neoadjuvant (PID1384 V1.1)Vinorelbine 25 / Cisplatin 75 / Radiation, Esophageal Cancer, neoadjuvant (PID1385 V1.1)
